Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNN4 | O15554 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL369213 | 0.83 | CA4 (0.39) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL21233040 | 0.77 | KDM4E (0.39) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL2800661 | 0.75 | CNR1 (0.34) | — | |
| SCHEMBL22951252 | 0.75 | KCNN4 (0.35) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL16663363 | 0.74 | KCNN4 (0.41) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL70574 | 0.73 | L3MBTL1 (0.44) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL69872 | 0.73 | KCNN4 (0.36) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL511015 | 0.73 | ALDH1A1 (0.38) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL8313319 | 0.73 | KCNN4 (0.36) | KCNN4KCNA3CYP11B1CYP11B2 | |
| SCHEMBL7254281 | 0.73 | GAA (0.48) | KCNN4KCNA3CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | EISAI CO., LTD. (JP) | 2007-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072896-A1 | Inhibitors of c-Jun N-terminal kinases for the treatment of neurodegenerative disorders relating to apoptosis and/or inflammation | NFKBIA, CHUK, MAP3K1 | KCNN4 4693/4885KCNA3 4254/4885CYP11B1 2119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.